

CLAIMS

That which is claimed is:

1. A method for classifying a tumor according to an expression profile of one or more genes, said method comprising:

detecting expression of at least a first gene in a test colon cell sample, wherein said first gene is a Group I gene,

wherein detection of increased expression of the first gene in the test cell sample relative to expression of the first gene in a control non-cancer cell sample indicates that the tumor is a Group I-type tumor.

2. The method of claim 1, wherein said first gene is an IGF2 gene.

3. The method of claim 2, wherein said method further comprises detecting expression of a second gene in the test sample, wherein said second gene is selected from the group consisting of: TTK, MAPKAPK2, MARCKS, BBS2, CETN2 CGI-148 protein, FGFR4, FHL3, FLJ22066, KIP2, MGC:29604, NQO2, and OGG1,

wherein detection of increased expression of the first and second genes in the test sample relative to expression of the first and second genes, respectively, in the control sample indicates that the tumor is a Group I-type tumor.

4. The method of claim 3, wherein said method further comprises detecting expression of a third gene in the test sample, wherein said third gene is selected from the group consisting of: TTK, MAPKAPK2, MARCKS, BBS2, CETN2 CGI-148 protein, FGFR4, FHL3, FLJ22066, KIP2, MGC:29604, NQO2, and OGG1,

wherein detection of increased expression of the first, second, and third genes in the test sample relative to expression of the first, second, and third genes, respectively, in the control sample indicates that the tumor is a Group I-type tumor.

5. The method of claim 1, wherein said expression is increased at least about 1.5-fold.

6. The method of claim 1, wherein said expression is increased at least about 2-fold.

7. The method of claim 1, wherein said expression is increased at least about 5-fold.

8. The method of claim 1, wherein said expression is increased at least about 10-fold.

9. A method for classifying a tumor according to an expression profile of one or more genes, said method comprising:

detecting expression of at least a first gene in a test colon cell sample, wherein said first gene is a Group II gene,

wherein detection of increased expression of the first gene in the test cell sample relative to expression of the first gene in a control non-cancer cell sample indicates that the tumor is a Group II-type tumor.

10. The method of claim 9, wherein said first gene is a member of the IFITM family of genes.

11. The method of claim 10, wherein said method further comprises detecting expression of a second gene in the test sample, wherein said second gene is ITAK or BIRC3/H-IAP1,

wherein detection of increased expression of the first and second genes in the test sample relative to expression of the first and second genes, respectively, in the control sample indicates that the tumor is a Group II-type tumor.

12. The method of claim 11, wherein said method further comprises detecting expression of a third gene in the test sample, wherein said third gene is ITAK or BIRC3/H-IAP1,

wherein detection of increased expression of the first, second, and third genes in the test sample relative to expression of the first, second, and third genes, respectively, in the control sample indicates that the tumor is a Group II-type tumor.

13. The method of claim 9, wherein said expression is increased at least about 1.5-fold.

14. The method of claim 9, wherein said expression is increased at least about 2-fold.
15. The method of claim 9, wherein said expression is increased at least about 5-fold.
16. The method of claim 9, wherein said expression is increased at least about 10-fold.
17. The method of claim 10, wherein said first gene is 1-8U.
18. The method of claim 10, wherein said first gene is 1-8D.
19. The method of claim 10, wherein said first gene is 9-27.
20. A method for classifying a tumor according to an expression profile of two or more genes, said method comprising:  
analyzing a test colon cell sample for expression of at least one Group I gene and at least one Group II gene,  
wherein detection of increased expression of said at least one Group I gene and said at least one Group II gene in the test cell sample relative to expression of said at least one Group I gene and said at least one Group II gene, respectively, in a control non-cancer cell sample indicates the tumor is a Group I+II-type tumor.
21. The method of claim 20, wherein said at least one Group I gene is an IGF2 gene and said at least one Group II gene is a member of the IFITM family of genes.
22. The method of claim 20, wherein said expression is increased at least about 1.5-fold for each of said at least one Group I gene and said at least one Group II gene.
23. The method of claim 20, wherein said expression is increased at least about 2-fold for each of said at least one Group I gene and said at least one Group II gene.

24. The method of claim 20, wherein said expression is increased at least about 5-fold for each of said at least one Group I gene and said at least one Group II gene.

25. The method of claim 20, wherein said expression is increased at least about 10-fold for each of said at least one Group I gene and said at least one Group II gene.